title: [Attention deficit hyperactivity disorder in adults. An overview].
abstract: Attention deficit hyperactivity disorder (ADHD), which is characterized by the inability to appropriately modulate attention and/or impulse control and hyperactivity, resulting in social, academic and occupational underachievement, is presently the topic of intensive discussion in German psychiatry. With a prevalence of 3-5%, ADHD is one of the most frequently seen disorders in child and adolescent psychiatry. With nearly 50% of childhood patients also affected during adulthood, this disorder is of much higher clinical significance for psychiatry than presumed thus far. The present review discusses current results of epidemiology, etiology, clinical symptoms and comorbidity, diagnostic assessment, pharmacotherapy, and psychological interventions for adults with ADHD.
authors.affiliation: Klinik für Psychiatrie und Psychotherapie, Zentralinstitut für Seelische Gesundheit, Mannheim. sobanski@kv.zi-mannheim.de
authors.forename: E
authors.initials: E
authors.lastname: Sobanski
authors.forename: B
authors.initials: B
authors.lastname: Alm
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis* / Q000453:epidemiology / Q000523:psychology / Q000628:therapy; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D015897:Comorbidity; D003937:Diagnosis, Differential; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology / Q000628:therapy; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D001523:Mental Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology / Q000628:therapy; D011613:Psychotherapy
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000697:Central Nervous System Stimulants; D018765:Dopamine Uptake Inhibitors